Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Glaucoma is the second leading cause of blindness and the first leading cause of irreversible
vision loss worldwide. The intraocular pressure (IOP) is the only modifiable risk factor for
all the spectrum of glaucoma. Reducing IOP in glaucoma increases the likelihood of preventing
progression of the disease and preserving the quality of life of the patient. Although
prostaglandin analogs (PGAs) and prostamides (PMs) are de facto first-line treatment options
for managing glaucoma, it is a common clinical experience to see their treatment effects
plateau to a level beyond which no clinically significant IOP reduction is likely. It is also
common to find minimal IOP treatment effects in the following conditions: patients with
normal tension glaucoma (NTG), patients with thicker central corneal thickness (CCT), and
patients with higher levels of corneal hysteresis (CH). CH is a possible proxy for the
ability of the scleral tissue around the optic nerve to dissipate energy away from the optic
nerve fibers. Netarsudil, a rho-kinase inhibitor was recently approved by the FDA for the
treatment of glaucoma and ocular hypertension. There is a paucity of research on the efficacy
of netarsudil in patients with NTG, thicker CCT, and higher levels of CH. This study aims to
investigate the above issues by evaluating the efficacy of netarsudil and bimatoprost in
subjects with NTG, thicker corneas, and higher levels of CH.
Hypotheses
- Netarsudil will have non-inferior efficacy compared to Bimatoprost in treating NTG.
- Corneal thickness and corneal hysteresis will reduce the efficacy of netarsudil similar
to bimatoprost in NTG.
- Netarsudil will change corneal thickness and corneal hysteresis similar to bimatoprost
in NTG.